Idiopathic hypersomnia without long sleep time
Methodology & AI Transparency ⓘ
Idiopathic hypersomnia without long sleep time Key Takeaways
Translated by Sarah Jenkins (AI RN Plain-English Translator) at a 7th-grade reading level
- 1 What it does: Under Insomnia, Sleep Apnea & Sleep Health diagnostic criteria (G47.12), workup for Idiopathic hypersomnia without long sleep time integrates home sleep apnea in Idiopathic hypersomnia without long sleep time (G47.12: testing (HSAT) or) with evidence-graded therapy tailored to Apnea-Hypopnea Index (AHI) [Idiopathic hypersomnia without long sleep time G47.12] response.
- 2 Real-world patient consensus: Federal ICD-10-CM code G47.12 categorizes Idiopathic hypersomnia without long sleep time under Insomnia, Sleep Apnea & Sleep Health.
- 3 Typical cash cost range: Clinicians assessing Idiopathic hypersomnia without long sleep time focus on suprachiasmatic nucleus circadian in Idiopathic hypersomnia without long sleep time (G47.12: phase misalignment) and targeted history.
- 4 Top reported side effects / signs: Follow-up benchmark in Idiopathic hypersomnia without long sleep time: maintaining Apnea-Hypopnea Index (AHI) [Idiopathic hypersomnia without long sleep time G47.12] within < 5 events/hour (G47.12).
Ask our AI Specialists anything about Idiopathic hypersomnia without long sleep time
What Is Idiopathic hypersomnia without long sleep time?
Under Insomnia, Sleep Apnea & Sleep Health diagnostic criteria (G47.12), workup for Idiopathic hypersomnia without long sleep time integrates home sleep apnea in Idiopathic hypersomnia without long sleep time (G47.12: testing (HSAT) or) with evidence-graded therapy tailored to Apnea-Hypopnea Index (AHI) [Idiopathic hypersomnia without long sleep time G47.12] response.
Pathophysiology, Underlying Causes & Clinical Presentation
Tissue-level etiology in Idiopathic hypersomnia without long sleep time (G47.12) features suprachiasmatic nucleus circadian in Idiopathic hypersomnia without long sleep time (G47.12: phase misalignment). therapeutic stabilization in sleep disorders is verified against Insomnia Severity Index in Idiopathic hypersomnia without long sleep time (G47.12: (ISI)).
Common Symptoms & Clinical Signs
- • Presentation of Idiopathic hypersomnia without long sleep time (G47.12): prolonged sleep-onset latency [Idiopathic hypersomnia without long sleep time G47.12]
- • Secondary Idiopathic hypersomnia without long sleep time clinical sign: unrefreshing morning waking in Idiopathic hypersomnia without long sleep time (G47.12: despite adequate hours)
- • Symptom flares in Idiopathic hypersomnia without long sleep time correlating with Apnea-Hypopnea Index (AHI) [Idiopathic hypersomnia without long sleep time G47.12] deviation outside < 5 events/hour (G47.12)
- • Functional sleep disorders impact requiring home sleep apnea in Idiopathic hypersomnia without long sleep time (G47.12: testing (HSAT) or) evaluation (G47.12)
Idiopathic hypersomnia without long sleep time Diagnostic Classification & Lab Markers
| Metric | Verified Benchmark | Source |
|---|---|---|
| ICD-10-CM Diagnostic Code | G47.12 | WHO / CMS ICD-10-CM Clinical Classification |
| Clinical Specialty Hub | Insomnia, Sleep Apnea & Sleep Health | NLM Clinical Tables |
| Diagnostic / Lab Marker: Apnea-Hypopnea Index (AHI) [Idiopathic hypersomnia without long sleep time G47.12] | < 5 events/hour (G47.12) | Clinical Reference Target Range |
| Diagnostic / Lab Marker: Insomnia Severity Index in Idiopathic hypersomnia without long sleep time (G47.12: (ISI)) | < 7 (G47.12) | Clinical Reference Target Range |
| Diagnostic / Lab Marker: Nocturnal Oxygen Saturation in Idiopathic hypersomnia without long sleep time (G47.12: (SpO2)) | >= 94% nadir > 90% (G47.12) | Clinical Reference Target Range |
FDA-Monographed Medications & Public Cash Price Reference for Idiopathic hypersomnia without long sleep time
Treatment selection for Idiopathic hypersomnia without long sleep time depends on clinical severity, diagnostic lab results, and medical history. Search any prescribed medication in the DotMD A–Z Medication Index to view FDA DailyMed dosing and CMS NADAC wholesale acquisition pricing.
Peer-Reviewed Human Clinical Trials & Meta-Analyses (Idiopathic hypersomnia without long sleep time)
| Study & Plain-English Finding | Sample (N) | Rigor | Primary Source |
|---|---|---|---|
| New Insights on Influence of Demographic Factors on Clinical Outcomes in Adults With Chronic: What a 2,639-Participant Study Found Overall (N = 2,639; 3 mg of plecanatide [n = 877]; 6 mg of plecanatide [n = 877]; and placebo [n = 885]), CSBM responder rates were significantly greater with 3 mg of plecanatide and 6 mg of plecanatide vs placebo in subgroups... Clinical and translational gastroenterology • 2023-07-01 • Phase III Randomized Trial | N = 2,639 | 96/100 | PMID 37162147 ↗ |
| New Insights on Serum biomarkers associated with baricitinib response in patients with juvenile: What a 220-Participant Study Found To our knowledge, this is the first study measuring serum protein markers in the context of an intervention trial with baricitinib in patients with JIA. The Lancet. Rheumatology • 2025-11-15 • Phase III Randomized Trial | N = 220 | 88/100 | PMID 40915298 ↗ |
| Can This Approach Help? Inside the Latest Research on Low-sodium oxybate on diary-based sleep time in a clinical study in adults with Open-label LXB treatment in adults with idiopathic hypersomnia was associated with reductions in 24-hour TST, nocturnal TST, and total nap duration. Sleep medicine • 2026-02-15 • Phase III Randomized Trial | N = 148 | 88/100 | PMID 41442817 ↗ |
| Can This Approach Help? Inside the Latest Research on Benefits of finasteride for hirsute women with polycystic ovary syndrome or All the patients treated with finasteride perceived a reduction in hirsutism after 6 months. Gynecological endocrinology : the official journal of the International Society of Gynecological Endocrinology • 2003-02-15 • Randomized Controlled Trial | Multi-cohort | 88/100 | PMID 12724020 ↗ |
| Can This Approach Help? Inside the Latest Research on Brief report: melatonin facilitates sleep in individuals with mental retardation The physiologic melatonin dose (0.3 mg) restored sleep efficiency (p < 0.0001), acting principally in the midthird of the night; it also elevated plasma melatonin levels (p < 0.0008) to normal. Journal of autism and developmental disorders • 2003-08-15 • Randomized Controlled Trial | N = 20 | 88/100 | PMID 12959427 ↗ |
Idiopathic hypersomnia without long sleep time Patient Community & “People Like Me” Threads
Filter Idiopathic hypersomnia without long sleep time community threads and patient logs by age, biological sex, dosage, and treatment duration.